Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy

Cancer Drug Resistance, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 25, 2024

Competing endogenous RNAs (ceRNAs) are transcripts that possess highly similar microRNA response elements (MREs). microRNAs (miRNAs) short, endogenous, single-stranded non-coding (ncRNAs) can repress gene expression by binding to MREs on the 3’ untranslated regions (UTRs) of target mRNA suppress promoting degradation and/or inhibiting protein translation. transcripts, circular (circRNAs), long (lncRNAs), and transcribed pseudogenes could share MREs, they compete for same pool miRNAs. These ceRNAs may affect level one another competing their shared This interplay between different constitutes a ceRNA network, which regulates many important biological processes. Cancer drug resistance is major factor leading treatment failure in patients receiving chemotherapy. It be acquired through genetic, epigenetic, various tumor microenvironment mechanisms. The involvement crosstalk its disruption chemotherapy attracting attention cancer research community. review presents an updated summary latest dysregulation causing across types chemotherapeutic classes. Interestingly, accumulating evidence suggests used as prognostic biomarkers predict clinical Nevertheless, detailed experimental investigations putative networks generated computational algorithms needed support translation therapeutic applications.

Language: Английский

---

Circular RNAs modulate cancer drug resistance: advances and challenges

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Acquired drug resistance is a main factor contributing to cancer therapy failure and high mortality, highlighting the necessity develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with closed loop structure, possess characteristics including stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated against various treatments, targeted therapy, chemotherapy, radiotherapy, immunotherapy. Therefore, targeting these aberrant may offer strategy improve efficiency therapy. Herein, we present summary most recently studied their regulatory roles on resistance. With advances artificial intelligence (AI)-based bioinformatics algorithms, could emerge as promising biomarkers targets

Language: Английский

---

Upregulated lncRNA LINC01128 in colorectal cancer accelerates cell growth and predicts malignant prognosis through sponging miR-363-3p

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(5)

Published: May 26, 2024

Colorectal cancer (CRC) refers to high-mortality tumors arising in the colon or rectum with a high rate of recurrence. The involvement long non-coding RNAs (lncRNAs) contributes treatment and prognosis evaluation CRC, brings new direction for radical cure patients. To identify pathological mechanism regulation lncRNA LINC01128 (LINC01128) on CRC cells, analyze its potential prognostic value.

Language: Английский

---

Circular RNAs: key players in tumor immune evasion

Molecular and Cellular Biochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

---

Expression Profile of Serum CircFUNDC1 and CircUHRF1 Can Differentiate Between Colorectal Cancer and Inflammatory Bowel Diseases (Ulcerative Colitis and Crohn's Disease)

Journal of Clinical Laboratory Analysis, Journal Year: 2025, Volume and Issue: unknown

Published: May 16, 2025

ABSTRACT Background Colorectal cancer ( CRC ) is a worldwide burden. Circular RNAs are promising biomarkers for diagnosing and prognosis of . Objective To investigate the possible association sera levels CircFUNDC1 CircUHRF1 expression with predisposition clinicopathological findings in , ulcerative colitis UC ), Crohn's disease CD Egyptian patients. Methods The serum were evaluated 113 subjects divided into four groups; (31), (26), (25) compared to healthy controls (31) using quantitative polymerase chain reaction. Results median values log2 fold change FC patients 9.11, 6.58, 6.17, respectively. It was upregulated all case groups. had significantly higher than p < 0.001). However, there no significant differences among patient groups ). medians log 2 −2.00, 3.33, 3.12, level lower group patients, difference between controls. Serum overexpressed or By Roc curve analysis, both genes can differentiate from inflammatory bowel IBD 0.05. Conclusion biomarker while

Language: Английский

---

LINC00513 promotes colorectal cancer malignant progression by binding with IGF2BP1 to enhance the stability of connective tissue growth factor mRNA

Epigenomics, Journal Year: 2024, Volume and Issue: 16(14), P. 985 - 998

Published: July 17, 2024

Aim: This study aimed to investigate the role of LINC00513 in colorectal cancer (CRC) progression. Materials & methods: Cell proliferation was evaluated using Counting Kit-8. migration detected with transwell assay. RNA pull-down applied for verifying interactions between LINC00513, IGF2BP1 and connective tissue growth factor (CTGF). Results: CTGF levels were upregulated CRC. Knockdown significantly inhibited malignant behavior CRC cells. increased mRNA stability by binding IGF2BP1. Furthermore, overexpression or reversed inhibitory effect shRNA on Conclusion: promoted cell behaviors through IGF2BP1/CTGF.

Language: Английский

---